Axitinib (off Label)
Axitinib + avelumab Phase 2 (MD Anderson)
Pfizer · Phase 2 · Completed · Enrollment 40
| Arm | Population | Dose | Estimand | Comparator | Efficacy |
|---|---|---|---|---|---|
| Axitinib + avelumab | R/M ACC (n = 28 evaluable) | axitinib 5 mg twice daily + avelumab | Single arm | n/r | confirmed objective response rate: 18%, primary analysismedian progression-free survival: 7.3 months, primary analysismedian overall survival: 16.6 months, primary analysis |
| Axitinib + avelumab, ACC-I subtype | ACC-I (exploratory biomarker analysis of 28 patients) | as above | Single arm | n/r | median progression-free survival: 1.8 months, updated analysis; exploratory |
| Axitinib + avelumab, ACC-II subtype | ACC-II (exploratory) | as above | Single arm | n/r | median progression-free survival: 11.4 months, updated analysis; HR 0.14 vs ACC-I |